SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility after a rapid price surge and subsequent collapse, sparking widespread accusations of a pump-and-dump scheme and market manipulation. Community sentiment is deeply polarized, with some traders hunting for dip-buying opportunities and potential recovery rallies, while others warn of a textbook rug pull and significant losses for retail investors.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a 13D filing from activist investor Shah Capital, which demands a major strategic overhaul including board reductions, share buybacks, and an evaluation of a potential company sale. While the community is divided between frustration over persistent price volatility and optimism regarding the value of the company's Matrix-M technology, sentiment is focused on the tension between activist pressure for immediate shareholder value and the company's long-term partnership-led strategy.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating intense social media hype as traders debate whether the asset is a legitimate moonshot or a speculative bubble prone to volatility. The community is actively discussing the coin's rapid price action and its potential influence on current market trends surrounding emerging community-driven tokens.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong diversification into automotive and AI-enabled devices against ongoing concerns regarding handset demand, memory supply constraints, and intensified competition. Community sentiment remains polarized, with many stakeholders focusing on the company's recent dividend increase and buyback program as a sign of confidence, while others debate the long-term impact of potential market share shifts in the mobile sector.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant interest as institutional accumulation and stablecoin usage reach record highs, while speculation surrounding the Clarity Act and potential regulatory shifts fuels market optimism. Community sentiment remains polarized between long-term bullish holders betting on institutional adoption and skeptics highlighting short-term price volatility and governance debates.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The IWM is experiencing significant volatility as market participants fixate on geopolitical tensions in the Middle East and the potential for a naval blockade in the Strait of Hormuz. While some investors are betting on a parabolic rally driven by peace deal optimism and FED liquidity, others remain highly skeptical, cautioning that broader macroeconomic risks and overbought technical conditions could trigger a sharp reversal.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility as investors react to reports of a White House executive order aimed at fast-tracking ibogaine research for veteran mental health care. The community is sharply divided between bulls betting on a massive short squeeze due to the stock's low float and bears warning of a potential 'sell the news' event following the rapid run-up.

CBOE Volatility Index

The VIX is experiencing significant upward pressure and high volatility as geopolitical instability in the Middle East intensifies, causing traders to rotate out of equities and into safety. Community sentiment is deeply divided, with many market participants actively debating whether current price levels represent a bottom or a precursor to further downside while monitoring critical thresholds like the 30 level on the VIX.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis (PSNL) is currently at the center of investor focus as the market closely monitors the company's progress in securing Medicare coverage for its NeXT Personal MRD test across breast cancer, lung cancer, and immunotherapy (IO) monitoring. Community discussion is sharply divided between bullish sentiment regarding the company's technology leadership in ultra-sensitive cancer detection and skepticism toward management's ability to maintain pace with competitors and meet aggressive regulatory timelines.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is attracting intense investor attention as the company prepares for a leadership transition, with Josh D'Amaro set to take the helm amid ongoing cost-cutting measures and a broader restructuring drive. The community remains deeply divided, balancing optimism over the streaming segment's profitability and upcoming theatrical slate against lingering concerns regarding management's strategic direction and recent box office performance.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest Update

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 10,843,213 shares, a growth of 31.7% from the March 15th total of 8,233,141 shares. Currently, 10.8% of...

Viridian Therapeutics (NASDAQ:VRDN) Trading Up 5.2% - What's Next?

Viridian Therapeutics (NASDAQ:VRDN) Trading 5.2% Higher - Here's What Happened...

Wedbush Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $31.00

Wedbush cut their price objective on shares of Viridian Therapeutics from $37.00 to $31.00 and set an "outperform" rating for the company in a report on Wednesday...

Top 3 Health Care Stocks Which Could Blast Off This Quarter

Undervalued companies in health care sector with low RSI values present buying opportunity: PepGen Inc (PEPG), KALA BIO Inc (KALA), Viridian Therapeutics Inc (VRDN)read more...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the...

The Goldman Sachs Group Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $31.00

The Goldman Sachs Group cut their price target on Viridian Therapeutics from $36.00 to $31.00 and set a "buy" rating on the stock in a research note on Tuesday...

AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease

Amgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.

Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Royal Bank Of Canada lowered their price target on Viridian Therapeutics from $42.00 to $30.00 and set an "outperform" rating for the company in a report on Tuesday...

<ul class="summary-bullets"><li>Amgen’s Phase 3 trial met its primary goal, with 77% of patients showing a strong improvement in eye bulging.</li><li>Stifel analyst Alex Thompson noted the higher proptosis rate but said Viridian’s Elegrobar could better stand out in the market.</li><li>Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen.</li></ul>Shares of Viridian Therapeutics (VRDN) plunged 23% on Monday to their lowest since June 3, 2025, extending a sharp selloff that began on March 30.Viridian shares&nbsp;had crashed last Monday after the firm <a href="https://stocktwits.com/news-articles/markets/equity/why-is-vrdn-stock-falling-today/cZERVHrRIZDk-in-thyroid-eye-disease-trials/cZ7xqdaRI83">reported</a> the Phase 3 results for Elegrobart in thyroid eye disease. While the study met its primary goal, showing strong reductions in eye bulging compared with placebo, improvements in inflammation were limited, and there were also reports of tinnitus.<h2 class="st-heading-2">Why Did The Stock Crash Today?</h2><a href="https://stocktwits.com/symbol/VRDN">VRDN shares</a> fell after Amgen reported positive results from a Phase 3 trial of Tepezza for thyroid eye disease. The study met its main goal, with 77% of patients showing a strong improvement in eye bulging over 24 weeks.Following the results, Stifel analyst Alex Thompson said Amgen’s Phase 3 results, with a 77% rate of proptosis response, were higher than Viridian’s Elegrobar, according to The Fly. However,&nbsp;Thomson noted that Viridian’s drug uses a simpler subcutaneous injection instead of an on-body infusion, which could help it stand out in the market. The analyst maintained a ‘Buy’ rating on Viridian shares.The Viridian REVEAL-1 trial met its main and key secondary goals at week 24. The study tested two dosing schedules, every four weeks and every eight weeks, against a placebo. Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen, compared to roughly 18% for placebo.Topline results from REVEAL-2, the second Phase 3 trial in chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026. The company plans to submit a Biologics License Application (BLA) to the FDA in the first quarter (Q1) of 2027.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits changed to ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.Chatter was largely positive despite the intraday slump, with one user calling the selloff “overdone.”<stembedurl>https://stocktwits.com/TKkamen/message/649478692</stembedurl>Another user expects the stock to climb to $25 by the end of the week. It is currently trading below $15.<stembedurl>https://stocktwits.com/Cracker36/message/649473609</stembedurl>Year-to-date, the stock has slumped more than 50%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/smx-stock-priming-for-multi-day-run-new-tracking-platform-pushes-shares-higher/cZJ4qGJRIYL">Is SMX Stock Priming For Another Multi-Day Run? New Tracking Platform Pushes Shares Up By 75%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

VRDN Stock Falls To 9-Month Lows – What’s The Amgen Connection?

Viridian shares continued to tumble after Amgen’s thyroid eye disease treatment trial showed a higher proptosis response rate.

Equity

Why Is Viridian Therapeutics Stock Sinking Monday?

Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over elegrobart's position in the TED market.read more...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VRDN News

VRDNViridian Therapeutics Inc